Submit to IJERPH Review for IJERPH Propose a Special Issue

Journal Menu

Journal Browser

Gynecologic Oncology: Diagnosis, Treatment and Prevention

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of International Journal of Environmental Research and Public Health (ISSN 1660-4601). This special issue belongs to the section "Women's Health".

Deadline for manuscript submissions: closed (31 March 2023) | Viewed by 12441

Share This Special Issue

Special Issue Editors

Dr. Aneta Cymbaluk- Płoska

E-Mail Website
Guest Editor

Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Al. Powstańców Wielkopolskich 72, 70-111 Szczecin, Poland
Interests: gynaecological surgery; gynecologic oncology; cancer prevention; hysterectomy; ovary; gynecologic surgical procedures; ovarian cancer; endometrial cancer; ovarian neoplasms

Prof. Dr. Elżbieta Grochans

E-Mail Website
Guest Editor

Department of Nursing, Pomeranian Medical University in Szczecin; Żołnierska 48, 71-210 Szczecin, Poland
Interests: menopause; women; quality of life; health; environmental factors; biological factors

Special Issue Information

Dear Colleagues,

One of today's challenges for oncology staff is to isolate high-risk patients for special surveillance.

Primary and secondary prevention in cancer cases is provided where it is possible.

Researchers are developing and searching for ever better biomarkers, algorithms and diagnostic imaging tests in order to achieve satisfactory results at the earliest stage of clinical advancement of neoplasms.

The search for better, more sensitive and specific factors, both prognostic and predictive for cancers of the reproductive organ, is still ongoing.

We must remember that women react emotionally from the beginning of the diagnosis. Our overriding goal is to improve the survival parameters of patients, but we must not forget about psychological support for our patients and their quality of life.

That is why most researchers try to combine their research and focus on achieving both of these goals at the same time—extending the time of survival while reducing its quality as little as possible.

I strongly encourage my colleagues to share any experiences on this important subject.

Dr. Aneta Cymbaluk- Płoska
Prof. Dr. Elżbieta Grochans
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Environmental Research and Public Health is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2500 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

cancers
diagnostic
prognostic factor
prediction
quality of life

Published Papers (6 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

13 pages, 527 KiB

Open AccessArticle

Long-Term Efficacy and Toxicity of Intensity-Modulated Radiotherapy in Bulky Cervical Cancer

by Yu Wang, Tan-Tzu Lo, Lily Wang, Shih-Tien Hsu, Sheau-Feng Hwang, Chien-Hsing Lu and Lou Sun

Int. J. Environ. Res. Public Health 2023, 20(2), 1161; https://doi.org/10.3390/ijerph20021161 - 9 Jan 2023

Cited by 8 | Viewed by 1691

Abstract

Treatment of bulky cervical cancer is associated with both high adverse effects and local recurrence rates with traditional box method radiotherapy. Intensity-modulated radiotherapy (IMRT) has been adopted for the treatment of cervical cancer in order to deliver more precise radiation doses to the target region. We retrospectively enrolled a total of 98 patients with cervical cancer ≥4 cm who completed IMRT and point A-based brachytherapy treatment. The median follow-up time of the cohort was 6.84 years, with the 5-year OS and DFS being 66.33% and 75.12%, respectively. In addition, 7.14% of patients experienced local recurrence, 12.24% had distant recurrence, 6.12% had both local and distant recurrence, and 3.06% had persistent disease. In the univariate analysis, lymph node metastasis, higher creatinine levels, higher initial CA-125 and receiving chemotherapy other than cisplatin were all associated with a worse PFS. A tumor size ≥6 cm was associated with an increased incidence of higher grade of acute diarrhea. Grade 3 late radiation proctitis and cystitis developed in 11.22% and 13.27% of patients, respectively. The local recurrence rates and overall efficiencies were not inferior to other studies involving traditional pelvic external beam radiation therapy with concurrent chemotherapy. The safety and efficacy of IMRT for bulky cervical cancer were acceptable. Full article

(This article belongs to the Special Issue Gynecologic Oncology: Diagnosis, Treatment and Prevention)

► Show Figures

Figure 1

12 pages, 1918 KiB

Open AccessArticle

Development and Validation of a Nomogram Based on Metabolic Risk Score for Assessing Lymphovascular Space Invasion in Patients with Endometrial Cancer

by Jingyuan Wang, Xingchen Li, Xiao Yang and Jianliu Wang

Int. J. Environ. Res. Public Health 2022, 19(23), 15654; https://doi.org/10.3390/ijerph192315654 - 25 Nov 2022

Cited by 3 | Viewed by 1415

Abstract

Objective: This study assessed the predictive value of the metabolic risk score (MRS) for lymphovascular space invasion (LVSI) in endometrial cancer (EC) patients. Methods: We included 1076 patients who were diagnosed with EC between January 2006 and December 2020 in Peking University People’s Hospital. All patients were randomly divided into the training and validation cohorts in a ratio of 2:1. Data on clinicopathological indicators were collected. Univariable and multivariable logistic regression analysis was used to define candidate factors for LVSI. A backward stepwise selection was then used to select variables for inclusion in a nomogram. The performance of the nomogram was evaluated by discrimination, calibration, and clinical usefulness. Results: Independent predictors of LVSI included differentiation grades (G2: OR = 1.800, 95% CI: 1.050–3.070, p = 0.032) (G3: OR = 3.49, 95% CI: 1.870–6.520, p < 0.001), histology (OR = 2.723, 95% CI: 1.370–5.415, p = 0.004), MI (OR = 4.286, 95% CI: 2.663–6.896, p < 0.001), and MRS (OR = 1.124, 95% CI: 1.067–1.185, p < 0.001) in the training cohort. A nomogram was established to predict a patient’s probability of developing LVSI based on these factors. The ROC curve analysis showed that an MRS-based nomogram significantly improved the efficiency of diagnosing LVSI compared with the nomogram based on clinicopathological factors (p = 0.0376 and p = 0.0386 in the training and validation cohort, respectively). Subsequently, the calibration plot showed a favorable consistency in both groups. Moreover, we conducted a decision curve analysis, showing the great clinical benefit obtained from the application of our nomogram. However, our study faced several limitations. Further external validation and a larger sample size are needed in future studies. Conclusion: MRS-based nomograms are useful for predicting LVSI in patients with EC and may facilitate better clinical decision-making. Full article

(This article belongs to the Special Issue Gynecologic Oncology: Diagnosis, Treatment and Prevention)

► Show Figures

Figure 1

14 pages, 334 KiB

Open AccessArticle

Evaluation of the Influence of Biological Factors during the Course of Treatment in Patients with Ovarian Cancer

by Daria Schneider-Matyka, Edyta Skwirczyńska, Maria Gaur, Beata Hukowska-Szematowicz, Sebastian Kwiatkowski, Marzena Mikla, Elżbieta Grochans and Aneta Cymbaluk-Płoska

Int. J. Environ. Res. Public Health 2022, 19(17), 10516; https://doi.org/10.3390/ijerph191710516 - 24 Aug 2022

Cited by 2 | Viewed by 1397

Abstract

The aim of this study was to evaluate the influence of β-endorphins and serotonin on the course of treatment, disease-free time, and overall survival of patients with ovarian cancer. This study may contribute to the identification of modifiable factors that may influence the treatment of ovarian cancer. The research was carried out in a group of 162 patients of which 139 respondents were included in the research; ovarian cancer was diagnosed in 78 of these patients. The study consisted of three stages. In the first stage of diagnostics, a survey among the patients was carried out. In the second stage—5 mL of blood was collected from each patient (n = 139) in the preoperative period to determine the concentration of β-endorphin and serotonin. In the third stage—blood samples were collected from those patients who had completed chemotherapy treatment or had surgery. Concentrations of β-endorphin and serotonin were measured by the Luminex method, using the commercial Luminex Human Discovery Assay kit. The average age of the patients was 62.99 years. The level of β-endorphin significantly differs among patients diagnosed with ovarian cancer and among patients in the control group (202.86; SD—15.78 vs. 302.00; SD—24.49). A lower level of β-endorphins was found in the patients with a recurrence of the neoplastic process compared to those without recurrence (178.84; SD—12.98 vs. 205.66; SD—13.37). On the other hand, the level of serotonin before chemotherapy was higher in the group of people with disease recurrence compared to those without recurrence (141.53; SD—15.33 vs. 134.99; SD—10.08). Statistically significantly positive correlations were found between the level of β-endorphin and both disease-free time (β-endorphin levels before chemotherapy: rho Spearman 0.379, p < 0.027; β-endorphin levels after chemotherapy: rho Spearman 0.734 p < 0.001) and survival time (β-endorphin levels before chemotherapy: rho Spearman 0.267, p < 0.018; β-endorphin levels after chemotherapy: rho Spearman 0.654 p < 0.001). 1. The levels of serotonin and β-endorphin levels are significantly related to ovarian cancer and change during treatment. 2. High mean preoperative concentrations of β-endorphins were significantly related to overall survival and disease-free time. Full article

(This article belongs to the Special Issue Gynecologic Oncology: Diagnosis, Treatment and Prevention)

15 pages, 1538 KiB

Open AccessArticle

How Does Hedonic Aroma Impact Long-Term Anxiety, Depression, and Quality of Life in Women with Breast Cancer? A Cross-Lagged Panel Model Analysis

by Marta Pereira, Célia Sofia Moreira, Pawel Izdebski, Alberto C. P. Dias, Cristina Nogueira-Silva and M. Graça Pereira

Int. J. Environ. Res. Public Health 2022, 19(15), 9260; https://doi.org/10.3390/ijerph19159260 - 28 Jul 2022

Cited by 2 | Viewed by 2421

Abstract

Depression and anxiety are common symptoms during and after adjuvant chemotherapy treatment for breast cancer (BC), with implications on quality of life (QoL). The present study evaluates the temporal relationship between anxiety, depression, and QoL (primary outcomes), as well as the impact of hedonic aroma (essential oils) on this relationship. This is a secondary analysis of a previously reported randomized controlled trial, with two groups: an experimental group (n = 56), who were subjected to the inhalation of a self-selected essential oil during chemotherapy, and a control group (n = 56), who were only subjected to the standard treatment. The hedonic aroma intervention occurred in the second (T1), third (T2), and fourth (T3) chemotherapy sessions, three weeks apart from each other. The follow-up (T4) assessments took place three months after the end of the treatment. Cross-lagged panel models were estimated in the path analysis framework, using structural equation modeling methodology. Regarding the control group, the cross-lagged panel model showed that anxiety at T1 predicted anxiety at T3, which in turn predicted both QoL and depression at T4. In the experimental group, hedonic aroma intervention was associated with stability of anxiety and QoL over time from T1 to T3, with no longitudinal prediction at T4. For women undergoing standard chemotherapy treatment, anxiety was the main longitudinal precursor to depression and QoL three months after chemotherapy. Thus, essential oils could complement chemotherapy treatment for early-stage BC as a way to improve long-term emotional and QoL-related adjustment. Full article

(This article belongs to the Special Issue Gynecologic Oncology: Diagnosis, Treatment and Prevention)

► Show Figures

Figure 1

12 pages, 855 KiB

Open AccessArticle

Endometrial Cancer in Pre-Menopausal Women and Younger: Risk Factors and Outcome

by Nurliza Abdol Manap, Beng Kwang Ng, Su Ee Phon, Abdul Kadir Abdul Karim, Pei Shan Lim and Maimunah Fadhil

Int. J. Environ. Res. Public Health 2022, 19(15), 9059; https://doi.org/10.3390/ijerph19159059 - 25 Jul 2022

Cited by 15 | Viewed by 2799

Abstract

Endometrial cancer is the sixth most common malignancy in women, and it is known to be a disease among postmenopausal women, but there is rising in the number of endometrial cancers among premenopausal women. This study aims to determine the clinical characteristic, risk factors, outcomes, and survival in pre and postmenopausal women with endometrial cancer in Malaysia. A retrospective study was conducted in Hospital Melaka that involved all women who were diagnosed with endometrial cancer in Hospital Melaka from January 2002 until July 2020. All subjects’ histopathological examination result was confirmed, and their clinical data were extracted and transferred into a standardized data checklist and analysed. A total number of 392 cases was obtained from the Annual Cancer Registry Hospital Melaka. However, only 281 cases were studied, including 44.8% premenopausal and 55.2% postmenopausal women. In the premenopausal group, there were higher incidence of obesity (30.8 + 8.6 vs. 28.9 + 7.1), younger age at menarche (12.7 + 1.5 vs. 13.3 + 1.6), lesser parity (1.47 vs. 3.26), and a higher number of nulliparous women (46.8% vs. 19.4%) as compared to postmenopausal group. The premenopausal group tends to be presented with a well-differentiated grading of tumour (52.4%) and a higher incidence of having concomitant endometrial hyperplasia (41.3%). The mean survival among the premenopausal group (200.3 + 7.9 months) is higher compared to postmenopausal group (153.9 + 6.5 months). These findings correlate with good survival and prognosis among the premenopausal group compared to the postmenopausal group. Full article

(This article belongs to the Special Issue Gynecologic Oncology: Diagnosis, Treatment and Prevention)

► Show Figures

Figure 1

15 pages, 536 KiB

Open AccessArticle

Bone Metastases of Endometrial Carcinoma Treated by Surgery: A Report on 13 Patients and a Review of the Medical Literature

by Jingyuan Wang, Yibo Dai, Tao Ji, Wei Guo, Zhiqi Wang and Jianliu Wang

Int. J. Environ. Res. Public Health 2022, 19(11), 6823; https://doi.org/10.3390/ijerph19116823 - 2 Jun 2022

Cited by 3 | Viewed by 2199

Abstract

Background: The aim of this study was to describe the clinicopathological features of endometrial cancer (EC) patients with bone metastases treated with surgery and to systematically review the literature. Methods: We performed a retrospective study to include patients with bone metastases of EC at Peking University People’s Hospital from 2000 to 2019. Clinicopathological features and survival outcomes were collected. Results: Among the 1662 patients with EC, 14 (0.84%) were identified with bone metastases, and all were treated surgically. Thirteen cases were analyzed. Four had bone metastases when diagnosed, and the remaining nine cases had bone metastases when first relapsed, with a median time to recurrence of 13 months (range, 5–144). The median age of the 13 patients was 58 years old (range, 45–76). Twelve were endometrioid carcinoma. The majority of sites of bone metastases were the pelvis, followed by the spine. The median overall survival (OS) was 57 months. We further combined the 13 patients with another 24 cases identified from literature research. There was no significant difference in clinicopathological characteristics between the patients with bone metastases when diagnosed and when they first relapsed. The median OS was numerically longer for patients with bone metastases when diagnosed than when they first relapsed (57 vs. 36 months, p = 0.084). Conclusions: Patients with bone metastases of EC might benefit from comprehensive treatment based on surgery, as symptoms can be palliated and survival can probably be extended. Full article

(This article belongs to the Special Issue Gynecologic Oncology: Diagnosis, Treatment and Prevention)

► Show Figures

Journal Menu

Journal Browser

Gynecologic Oncology: Diagnosis, Treatment and Prevention

Share This Special Issue

Special Issue Editors

Special Issue Information

Keywords

Published Papers (6 papers)

Research

Further Information

Guidelines

MDPI Initiatives

Follow MDPI